HALOZYME THERAPEUTICS INC (HALO)

US40637H1095 - Common Stock

39.12  +0.15 (+0.38%)

After market: 39.12 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
443.3M
65.66%		660.1M
48.91%		829.253M
25.63%		973.44M
17.39%
EBITDA
YoY % growth
278.9M
88.96%		339M
21.55%		424.93M
25.35%		563.25M
32.55%		N/AN/AN/AN/A
EBIT
YoY % growth
275.9M
91.20%		289.4M
4.89%		340.074M
17.51%		477.05M
40.28%
Operating Margin
62.24%43.84%41.01%49.01%
EPS
YoY % growth
1.92
113.33%		2.22
15.62%		2.78
25.23%		3.76
35.27%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		0.71
51.91%
Revenue
Q2Q % growth		203.77M
25.71%
EBITDA
Q2Q % growth		111.94MN/AN/AN/AN/A
EBIT
Q2Q % growth		89.741M
66.80%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 0.82
70.83%		0.84-0.02-2.55%
Q3 2023
Q2Q % growth		 0.75
1.35%		0.720.033.96%
Q2 2023
Q2Q % growth		 0.74
39.62%		0.640.1015.31%
Q1 2023
Q2Q % growth		 0.47 0.49-0.02-3.40%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 230.039M
26.74%		235.76M-5.721M-2.43%
Q3 2023
Q2Q % growth		 216M
3.35%		220.43M-4.43M-2.01%
Q2 2023
Q2Q % growth		 221M
45.01%		203.95M17.05M8.36%
Q1 2023
Q2Q % growth		 162.1M
38.19%		179.02M-16.92M-9.45%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS-8.06% -17.65% 0.05% -15.15%
Revenue-5.83% -16.45% -0.02% -17.85%